Cytokine responsiveness of CD8 + T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients

Table 1 IL-2 responsiveness in peripheral blood T cells before and after DC vaccination

Patient ID	Overall survival (months)	Pre-DC Vax CD3+CD8+ EC-50	Post-DC Vax CD3+CD8+ EC-50	Pre-DC Vax CD3+CD4+ EC50	Post-DC Vax CD3+CD4+ EC-50
1-708	33.83	128.2	13.16	3.528	13.39
34-730	16.23	126.2	66.01	20.73	0.005
36-852	>43.9	27.95	0.017	4.407	0.002
6-815	17.3	1.854	0.196	0.002	2.355
19-539	34.9	8.223	14.27	1.386	1.178
GAA-03	35.3	60.52	18.63	29.64	0.003
GAA-05	11.73	38.2	34.69	11.43	5.245
GAA-07	17.2	16.52	6.07	5.446	5.237
GAA-09	11.0	31.19	22.38	7.2	7.7
AVERAGE:		50.70	19.15	9.31	3.90
SEM:		16.90	6.38	3.10	1.30
T-test:		0.045		0.223

¹The EC-50 for IL-2 responsiveness (pSTAT-5) was calculated in CD3⁺8⁺ and CD3⁺CD4⁺ peripheral blood T cells after a 20-minute stimulation with increasing dosages of IL-2, FACS analysis, and log transformation.